Ethypharm - Development - Business development
Business development

Ethypharm is ready to make deals happen

Ethypharm is interested in discussing all in-licensing and partnering opportunities which fit with its development ambition. We are aligned behind a clear strategic mandate and our business development team and internal due diligence experts are ready to make these opportunities succeed.

A clear strategic focus

Our Corporate Development activities are fully focused on the reinforcement of our position along three axes:

  • Commercial presence in Europe : any type of deal (assets and in-licensing, or company acquisition) which will reinforce our position in our existing markets or allow us to expand our presence in Europe will be given consideration.
  • Central nervous system and critical care : we are looking for already marketed or late-stage R&D branded prescription medicines to complement our existing portfolio of products in these two major areas.
  • Rare diseases in China : our longstanding affiliate, which has full value-chain capabilities and deep knowledge of the local fast-changing environment, is a partner of choice for international companies wishing to register and commercialise their rare disease medicines in China.

Business development

An experienced and supported team to drive the deal process

Ethypharm’s dedicated Corporate Development team is composed of professional individuals who have a proven deal-making track record. Acting both as scouts and deal process managers, each member of the team can rely on the full support of our internal experts to conduct an initial assessment and due diligence in a timely manner.

Our robust internal process also guarantees that our shareholders are fully aligned from the start and ready to support the financing of the deal if needed.

If you are looking to create value with an asset that fits our strategic focus, you can find us at most major international partnering events. Alternatively, send us a message via our contact page and we will get back to you shortly.

Contact us